Quarterly ResultMay 7, 2026, 04:22 PM
ImageneBio Secures $30M Financing; Advances IMG-007 Programs
AI Summary
ImageneBio reported its first-quarter 2026 financial results, including a net loss of $10.6 million. The company successfully completed a private placement in April 2026, raising approximately $30 million, which extends its cash runway into Q1 2028. ImageneBio also provided updates on its lead program, IMG-007, progressing its Phase 2b ADAPTIVE trial for atopic dermatitis and planning a Phase 2 study for alopecia areata in 2026.
Key Highlights
- Completed $30 million private placement in April 2026, extending cash runway into Q1 2028.
- IMG-007 Phase 2b ADAPTIVE trial for atopic dermatitis progressing; topline data expected Q4 2027.
- Plans to initiate Phase 2 study of IMG-007 in alopecia areata in 2026, with initial data in 2028.
- Cash, cash equivalents, and marketable securities were $117.2 million as of March 31, 2026.
- Q1 2026 R&D expenses increased to $6.0 million from $4.0 million in Q1 2025.
- Q1 2026 G&A expenses increased to $6.1 million from $2.8 million in Q1 2025.
- Net loss for Q1 2026 was $10.6 million, compared to $9.1 million in Q1 2025.
- Preclinical data on IMG-007 to be presented at 83rd Annual SID Meeting in May 2026.